Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings show that macrophage NCOR1 blocks the pro-atherogenic functions of PPARγ in atherosclerosis and suggest that stabilizing the NCOR1-PPARγ binding could be a promising strategy to block the pro-atherogenic functions of plaque macrophages and lesion progression in atherosclerotic patients.
|
31529020 |
2020 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR<sub>γ</sub>) has recently been identified as an attractive target for atherosclerosis intervention.
|
31099308 |
2019 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, loss of function of PPARγ enhances cardiovascular events and atherosclerosis in the vascular endothelium.
|
31055770 |
2019 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Aortic wall shows histopathological evidence of atherosclerosis in obesity group which is more evident in atherosclerotic group, and milder changes upon receiving PPARγ agonist.
|
30612469 |
2019 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Metabolic reprogramming in atherosclerosis: Opposed interplay between the canonical WNT/β-catenin pathway and PPARγ.
|
31153873 |
2019 |
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
<b>Results:</b> Our results indicated that the protein levels of HMGB1, TLR4, and pro-inflammatory cytokines including IL-1β, TNF-α were elevated with the development of atherosclerosis in CUMS mice, while the expressions of PPARγ, LXRα, and ABCA1 declined.
|
30881312 |
2019 |
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
On the whole, these results demonstrate that quercetin prevents the development of AS in apoE‑/‑ mice by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1.
|
31524223 |
2019 |
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
PPARγ and PPARα belong to a receptor family of ligand-activated transcription factors involved in the regulation of inflammation, cellular glucose uptake, protection against atherosclerosis and endothelial cell function.
|
30697628 |
2019 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, PPARγ antagonist GW9662 co-administration mostly blocked these effects, suggesting the important role of PPARγ pathways in mediating 20(S)-Rg3 effects in macrophage polarization and atherosclerosis progression.
|
29867472 |
2018 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
It is of great interest to understand the stereochemical selectivity of 20(R/S)-Rg3 and explore whether differential PPARγ activation by Rg3 stereoisomers, if it exists, could lead to differential physiological outcome and therapeutic effects in diabetic atherosclerosis.
|
29566305 |
2018 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
According to the results of a preliminary study, it was hypothesized that the effects of adiponectin (APN) on the improvement of atherosclerosis may be associated with adipocyte differentiation and peroxisome proliferator‑activated receptor γ (PPARγ).
|
29115433 |
2018 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results suggested that AGP plays a significant role in the initiation/progression of diabetes-related atherosclerosis through PPARγ activation.
|
29355589 |
2018 |
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Previously, we reported that selective deletion of PPARγ (peroxisome proliferator-activated receptor γ) in vascular smooth muscle cells resulted in concurrent loss of PVAT and enhanced atherosclerosis in mice.
|
29954752 |
2018 |
Atherosclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recent advances on the emerging role of CD36 and GHRP hexarelin in regulating PPARγ downstream actions with benefits on atherosclerosis, hepatic cholesterol biosynthesis and fat mitochondrial biogenesis are summarized here.
|
29883404 |
2018 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor γ (PPARγ) is involved in the pathology of numerous diseases including atherosclerosis, diabetes, obesity, and cancer.
|
29628981 |
2018 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In cardiovascular disease, PPARγ inhibits atherosclerosis but TR4 enhances atherosclerosis through increasing foam cell formation.
|
28527578 |
2017 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
The wide spectrum of PPAR-γ activation effects may be beneficial for treatment of various cardiovascular conditions as atherosclerosis, hypertension and aortic aneurysm, including surgical interventions.
|
27855608 |
2017 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Activation of macrophage ABCA1/G1 expression and cholesterol efflux is believed one of the mechanisms by which PPARγ inhibits atherosclerosis.
|
27890613 |
2017 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
And the underlying mechanism of OA on atherosclerosis may involve in lipid metabolism genes: PPARγ, AdipoR1, and AdipoR2.
|
28338883 |
2017 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study highlights the functional dichotomy of intracellular versus extracellular NAMPT, and unveils a critical role for the iNAMPT-peroxisome proliferator-activated receptor γ axis in atherosclerosis.
|
28408371 |
2017 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor-γ (PPARγ), liver X receptor-α (LXRα), and PPARγ co-activator-1α (PGC-1α) are nuclear factors that regulate lipid metabolism and inflammation implicated in atherosclerosis.
|
27016616 |
2016 |
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In the atherosclerosis mice, GQ-177 inhibited atherosclerotic lesion progression, increased plasma HDL and mRNA levels of PPARγ and ATP-binding cassette A1 in atherosclerotic lesions.
|
26706782 |
2016 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
The mechanisms by which endothelial PPAR-γ regulates inflammatory responses and protects against atherosclerosis remain unclear.
|
26566726 |
2016 |
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Notably, additional Tg(PPAR-γ) or pharmacological activation of PPAR-γ effectively prevented Tg(DNMT1)-induced proinflammatory cytokine production in macrophages and AS development in the mouse model.
|
27530451 |
2016 |
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPARG) is a transcription factor involved in atherosclerosis and related diseases.
|
27264718 |
2016 |